<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1507">
  <stage>Registered</stage>
  <submitdate>17/12/2003</submitdate>
  <approvaldate>17/12/2003</approvaldate>
  <actrnumber>ACTRN12606000379516</actrnumber>
  <trial_identification>
    <studytitle>ANZ 0001 Capecitabine vs CMF in Advanced Breast Cancer</studytitle>
    <scientifictitle>A phase III trial to evaluate oral chemotherapy with Capecitabine versus standard chemotherapy with CMF in advanced breast cancer</scientifictitle>
    <utrn />
    <trialacronym>ANZ 0001(Capecitabine)</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR436</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>ANZ 0001 is  an unblinded, multicentre, randomized phase III clinical trial of 465  women with advance disease and not suited to intensive chemotherapy. This study aims to determine whether daily oral chemotherapy with capecitabine is preferable to standard intermittent chemotherapy with CMF in such people.

This trial has 3 treatment arms: Intermittent Capecitabine; Continuous Capecitabine; Standard CMF (CMF) - (oral cyclophosphamide days 1-14; methotrexate and 5-Fluorouracil both IV days 1 and 8)

Intermittent Capecitabine (IC) 
Intermittent daily oral chemotherapy with 
capecitabine 2000 mg/m2/day days 1-14, reviewed and repeated every 3 weeks.  
The dose of capecitabine is increased to 2500 mg/m2/day if there is no toxicity equal to or greater than grade 1 in cycles 1 and 2.
Patients with moderate renal impairment (calculated creatinine clearance of 30 - 50 mL/minute) should not have their dose escalated above 2000 mg/m2 per day.

Or

Continuous Capecitabine (CC)
Continuous daily oral chemotherapy with 
capecitabine 1300 mg/m2/ day days 1-21 reviewed and repeated every 3 weeks.  
There is no dose escalation.  </interventions>
    <comparator>Standard CMF (CMF)
Standard intermittent combination chemotherapy with oral cyclophosphamide 100mg/m2 days 1-14, methotrexate 40mg/m2 IV days 1 and 8, 5-Fluorouracil 600mg/m2 IV days 1 and 8 reviewed and repeated every 4 weeks.  
There is no dose escalation.

Prednisone 40 mg /m2 p.o.  days 1-14 may be used with CMF at the investigators discretion; this intention must be documented prior to randomisation.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary objective is to compare oral chemotherapy with capecitabine to standard intermittent combination chemotherapy with CMF in terms of quality adjusted time to progression</outcome>
      <timepoint>quality adjusted time to progression</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare time to progression.</outcome>
      <timepoint>from randomisation to disease progression or death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumour response rates in patients with measurable disease.</outcome>
      <timepoint>using RECIST in those with measurable disease</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient acceptability and other aspects of health-related quality of life (HRQL).</outcome>
      <timepoint>patient and investigator ratings</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival.</outcome>
      <timepoint>from randomisation to death, all causes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (side effects).</outcome>
      <timepoint>Adverse events throughout trial</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Compliance.</outcome>
      <timepoint>pill counts</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Marginal cost-effectiveness.</outcome>
      <timepoint>in patient days, ambulatory visits, expensive drugs</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologic or cytologic diagnosis of breast cancer with at least one of the following: distant metastasis (including just supraclavicular nodes), local invasion of adjacent non-breast tissue ie T4 or N2 or N3, local recurrence following mastectomy; Treatment with palliative intent, i.e. without realistic hope of cure; Suitable for protocol chemotherapy with either CMF or capecitabine; ECOG performance status of 0 to 3; Neutrophil count greater than or equal to 1.5 x 10 (9)/L and Platelet count greater than or equal to 75 x 10 (9)/L; Creatinine clearance greater than or equal to 30 mL/minute according to the Cockcroft-Gault Formula; Serum total bilirubin &lt;50 umol/L; Accessible for treatment and follow-up; Written informed consent; Baseline HRQL forms completed OR the patient cannot read English.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous chemotherapy for advanced breast cancer; Less than 6 months following the last dose of adjuvant chemotherapy; Unsuitable for protocol therapy with either CMF or capecitabine, e.g.  side effects with 5 FU suggestive of dihydropyrimidine dehydrogenase deficiency; GI disease precluding oral chemotherapy; serious uncontrolled infection; Indication for chemotherapy more intensive than CMF or capecitabine; Brain and/or leptomeninges as the only sites of documented disease; Age &lt;18 years (there is no upper age limit); Pregnant or breast-feeding women; Investigational drug therapy within 30 days prior to randomisation; Concurrent anticancer therapy (any radiation must be completed at least 4 weeks before randomisation); Other malignancy within the last 5 years except adequately treated basal cell or squamous cell carcinoma of skin or in-situ carcinoma of the cervix; Treatment with the antiviral agent sorivudine, or related compounds such as brivudine</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The ANZ BCTG Statistical Centre at the NHMRC Clinical Trials Centre, University of Sydney will provide a central randomisation service by fax for all Australian and New Zealand institutions. At the time of study entry all participants were allocated a treatment arm via a phone/fax randomization system and treatment was supplied in accordance with the randomization allocation.</concealment>
    <sequence>Computer generated stratified blocks.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/06/2001</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>465</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australian New Zealand Breast Cancer Trials Group Ltd</primarysponsorname>
    <primarysponsoraddress>Locked Bag 7, HRMC, NSW 2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australian New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>Locked Bag 7, HRMC, NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche Products Pty Ltd</fundingname>
      <fundingaddress>31 Victoria Avenue
Castle Hill NSW 2154
AUSTRALIA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Chemotherapy can improve both the length and qualtiy of life in women with advanced breast cancer, however the best approach is unclear for women unsuited to intensive chemotherapy.  This randomised trial aims to find out whether simple daily oral chemotherapy (Capecitabine) or standard chemotherapy including injections (CMF) is best for such women.  The study looks at the effects of disease and treatment on both length and quality of life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bankstown-Lidcombe Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/11/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/11/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/09/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Concord Repatriation General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dubbo Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/04/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/05/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Flinders Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/02/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/04/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>12/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lismore Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/04/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/09/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>31/07/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/10/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/07/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/02/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/01/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>11/10/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/10/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/08/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God</ethicname>
      <ethicaddress />
      <ethicapprovaldate>5/04/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent’s Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>18/10/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent’s Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/03/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tamworth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/10/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Toowoomba Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/10/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tweed Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/07/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wellington Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/12/2000</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/05/2001</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Private Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Australian New Zealand Breast Cancer Trials Group National Group Coordinator - Professor John F Forbes</name>
      <address>Australian New Zealand Breast Cancer Trials Group Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Administrative Officer, Data Management</name>
      <address>Australian New Zealand Breast Cancer Trials Group Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49850166</phone>
      <fax>+61 2 49850141</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>